Buchumschlag

Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial$dbrief report : clinical trials and observations

The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chem...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bärtsch, Marc-Andrea (VerfasserIn) , Schlenzka, Jana (VerfasserIn) , Hielscher, Thomas (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn) , Sauer, Sandra (VerfasserIn) , Merz, Maximilian (VerfasserIn) , Mai, Elias K. (VerfasserIn) , Müller-Tidow, Carsten (VerfasserIn) , Luntz, Steffen P. (VerfasserIn) , Jauch, Anna (VerfasserIn) , Brossart, Peter (VerfasserIn) , Görner, Martin (VerfasserIn) , Klein, Stefan (VerfasserIn) , Glaß, Bertram (VerfasserIn) , Reimer, Peter (VerfasserIn) , Graeven, Ullrich (VerfasserIn) , Fenk, Roland (VerfasserIn) , Hänel, Mathias (VerfasserIn) , Metzler, Ivana von (VerfasserIn) , Lindemann, Hans W. (VerfasserIn) , Scheid, Christoph (VerfasserIn) , Blau, Igor-Wolfgang (VerfasserIn) , Salwender, Hans (VerfasserIn) , Noppeney, Richard (VerfasserIn) , Besemer, Britta (VerfasserIn) , Weisel, Katja (VerfasserIn) , Goldschmidt, Hartmut (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 17 April 2025
In: Blood
Year: 2025, Jahrgang: 145, Heft: 16, Pages: 1780-1787
ISSN:1528-0020
DOI:10.1182/blood.2024027342
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1182/blood.2024027342
Volltext
Verfasserangaben:Marc-Andrea Baertsch, Jana Schlenzka, Thomas Hielscher, Marc S. Raab, Sandra Sauer, Maximilian Merz, Elias Karl Mai, Carsten Müller-Tidow, Steffen Luntz, Anna Jauch, Peter Brossart, Martin Goerner, Stefan Klein, Bertram Glass, Peter Reimer, Ullrich Graeven, Roland Fenk, Mathias Haenel, Ivana von Metzler, Hans W. Lindemann, Christof Scheid, Igor-Wolfgang Blau, Hans J. Salwender, Richard Noppeney, Britta Besemer, Katja C. Weisel, and Hartmut Goldschmidt, for the German-Speaking Myeloma Multicenter Group
Beschreibung
Zusammenfassung:The multicenter, phase 3 German-Speaking Myeloma Multicenter Group (GMMG) ReLApsE trial randomized patients with relapsed and/or refractory multiple myeloma (RRMM) equally to lenalidomide/dexamethasone (LEN/DEX; 25 mg days 1-21, DEX 40 mg weekly, in 4-week cycles) reinduction, salvage high-dose chemotherapy (sHDCT; melphalan 200 mg/m2), autologous stem cell transplantation (ASCT), and LEN maintenance (10 mg/d; transplant arm, n = 139) vs continuous LEN/DEX (control arm, n = 138). Ninety-four percent of patients had received frontline HDCT/ASCT. We report an updated analysis of survival end points with a median follow-up of 99 months. Median progression-free survival (PFS) was 20.5 and 19.3 months in the transplant and control arm, respectively (hazard ratio [HR], 0.98; P = .9). Median overall survival (OS) was 67.1 and 62.7 months, respectively, (HR 0.89; P = .44). Landmark analyses from sHDCT and the contemporaneous LEN/DEX cycle 5 were performed because of 29% dropout of patients before sHDCT/ASCT in the transplant arm but did not reveal significant differences in PFS/OS. Time to progression after frontline HDCT/ASCT was a prognostic factor but did not predict benefit from sHDCT/ASCT. The GMMG ReLApsE trial does not support use of sHDCT/ASCT in RRMM after frontline HDCT/ASCT. This trial was registered at www.clinicaltrialsregister.eu as #EudraCT2009-013856-61.
Beschreibung:Gesehen am 03.06.2025
Beschreibung:Online Resource
ISSN:1528-0020
DOI:10.1182/blood.2024027342

Ähnliche Einträge